Disseminated, hormone-sensitive PCa (HSPC) is managed with androgen deprivation therapy to target the androgen receptor (AR), but after a median of 24–36 months, the tumor recurs with re-activation of the AR as castration-resistant PCa (CRPC) [4]. This evidence concerns the gene AR and neoplasm.